| __timestamp | Celldex Therapeutics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 101881000 | 22732000 |
| Thursday, January 1, 2015 | 4011000 | 29245000 |
| Friday, January 1, 2016 | 102026000 | 33206000 |
| Sunday, January 1, 2017 | 96171000 | 31152000 |
| Monday, January 1, 2018 | 66449000 | 10136000 |
| Tuesday, January 1, 2019 | 42672000 | 45546000 |
| Wednesday, January 1, 2020 | 42534000 | 43367000 |
| Friday, January 1, 2021 | 3068000 | 81413000 |
| Saturday, January 1, 2022 | 1400000 | 139304000 |
| Sunday, January 1, 2023 | 3008000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
Cracking the code
In the competitive landscape of biotechnology, cost efficiency is a critical metric for success. This analysis compares the cost of revenue for Halozyme Therapeutics, Inc. and Celldex Therapeutics, Inc. over a decade, from 2014 to 2023. Halozyme has demonstrated a remarkable upward trend, with its cost of revenue peaking at approximately $192 million in 2023, a staggering 740% increase from 2014. In contrast, Celldex's cost of revenue has fluctuated, reaching its highest point in 2016 at around $102 million, before declining significantly to just over $3 million in 2023. This divergence highlights Halozyme's strategic efficiency improvements, while Celldex faces challenges in maintaining cost stability. As the biotech industry evolves, these insights underscore the importance of financial agility and strategic planning in sustaining growth and competitiveness.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Cost of Revenue Trends: Perrigo Company plc vs Celldex Therapeutics, Inc.
Cost of Revenue Trends: Veracyte, Inc. vs Celldex Therapeutics, Inc.
Cost of Revenue Comparison: MorphoSys AG vs Celldex Therapeutics, Inc.